Replies to post #13183 on Sorrento Therapeutics Inc (SRNE)

[1776club]

...and there you have it. Investors (institutions) willing to buy whatever shares SORRENTO makes available and past investments increasing in value.

Even at $2.25 a share plus assets and a $350 million burn a year the company has enough assets to go 4 years with no income. They do have increasing income YOY and major wins starting to take stage already this year and ramping up in the years ahead.

Even though we, all of us do, have a frustration on the lack of information coming from the company upon reflection I am glad to see it. Why, it shows me that a R&D guy who is a cheerleader for his team and always optimistic which carried through in his pronouncements, that fell flat on their face, has begun his metamorphous from R&D to management and production of a large company which is tough to do. I wish him, and of course "we", well.

[dia76ca]

8 UPDATES FROM THE 10K that most interested me.
1. Sorrento has 20.4 million shares of CELU ...currently valued at about $200 million. Can you name another small biotech with a better investment!

2. COVISTIX EUA applications to WHO, Canada and US FDA "have been completed." Q1 sales revenue from Mexico and Brazil will be significant.

3. SEMDEXA is preceding well. It currently has Fast Track and will be requesting Breakthrough Designation and Priority Review. Marketing network is in place for late 2022 to mid-2023 sales. Multi-Billion Sciatica sales potential.

4. COVI-MSC for ARDS data from US and Pivotal Brazil study available any day now. To be followed by Covid LongHauler study. Both are potential blockbusters.

5. MAYO CLINIC ADNAB drug conjugate program advancing into several programs. Potentially over a dozen combinations targeting many cancer combinations. Both ADNAB and DAR-T will leverage the huge antibody library beginning with PD-1, PD-L1, CD38, CD47, BCMA, CTLA-4, CD123, CD47, LAG3, ROR1, VEAGFR2, CR2 and CD137 among others!

6.DAR-T off the shelf enters clinic. Dozens of potential targets. Preclinical results point to being safer and more powerful than CAR-T!

7.COVISHIELD is now in phase 1 in healthy volunteers. Nose drops and 2 minute injections which treat all past, present and expected variations.

8. COVI-GeneMAb IND this year. $34 million DARPA grant will fund testing for both treatment and prevention of Covid. Effect is expected to last over several months.

I forsee a dramatic revenue increase in 2022 with a stunning portfolio of Covid, Cancer and non-opioid pain products!